Literature DB >> 17310251

Factor B structure provides insights into activation of the central protease of the complement system.

Fin J Milder1, Lucio Gomes, Arie Schouten, Bert J C Janssen, Eric G Huizinga, Roland A Romijn, Wieger Hemrika, Anja Roos, Mohamed R Daha, Piet Gros.   

Abstract

Factor B is the central protease of the complement system of immune defense. Here, we present the crystal structure of human factor B at 2.3-A resolution, which reveals how the five-domain proenzyme is kept securely inactive. The canonical activation helix of the Von Willebrand factor A (VWA) domain is displaced by a helix from the preceding domain linker. The two helices conformationally link the scissile-activation peptide and the metal ion-dependent adhesion site required for binding of the ligand C3b. The data suggest that C3b binding displaces the three N-terminal control domains and reshuffles the two central helices. Reshuffling of the helices releases the scissile bond for final proteolytic activation and generates a new interface between the VWA domain and the serine protease domain. This allosteric mechanism is crucial for tight regulation of the complement-amplification step in the immune response.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17310251     DOI: 10.1038/nsmb1210

Source DB:  PubMed          Journal:  Nat Struct Mol Biol        ISSN: 1545-9985            Impact factor:   15.369


  42 in total

Review 1.  Conformational selection in trypsin-like proteases.

Authors:  Nicola Pozzi; Austin D Vogt; David W Gohara; Enrico Di Cera
Journal:  Curr Opin Struct Biol       Date:  2012-06-03       Impact factor: 6.809

2.  Molecular mechanisms of complement evasion: learning from staphylococci and meningococci.

Authors:  Davide Serruto; Rino Rappuoli; Maria Scarselli; Piet Gros; Jos A G van Strijp
Journal:  Nat Rev Microbiol       Date:  2010-06       Impact factor: 60.633

3.  Kinetic dissection of the pre-existing conformational equilibrium in the trypsin fold.

Authors:  Austin D Vogt; Pradipta Chakraborty; Enrico Di Cera
Journal:  J Biol Chem       Date:  2015-07-27       Impact factor: 5.157

Review 4.  Complement-targeted therapeutics.

Authors:  Daniel Ricklin; John D Lambris
Journal:  Nat Biotechnol       Date:  2007-11       Impact factor: 54.908

Review 5.  The expanding diversity of serine hydrolases.

Authors:  Istvan Botos; Alexander Wlodawer
Journal:  Curr Opin Struct Biol       Date:  2007-09-24       Impact factor: 6.809

6.  The structure of C2b, a fragment of complement component C2 produced during C3 convertase formation.

Authors:  Vengadesan Krishnan; Yuanyuan Xu; Kevin Macon; John E Volanakis; Sthanam V L Narayana
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-02-20

7.  Structural and functional analysis of a C3b-specific antibody that selectively inhibits the alternative pathway of complement.

Authors:  Kenneth J Katschke; Scott Stawicki; Jianping Yin; Micah Steffek; Hongkang Xi; Lizette Sturgeon; Philip E Hass; Kelly M Loyet; Laura Deforge; Yan Wu; Menno van Lookeren Campagne; Christian Wiesmann
Journal:  J Biol Chem       Date:  2009-02-05       Impact factor: 5.157

8.  Functional basis of protection against age-related macular degeneration conferred by a common polymorphism in complement factor B.

Authors:  Tamara Montes; Agustín Tortajada; B Paul Morgan; Santiago Rodríguez de Córdoba; Claire L Harris
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-02       Impact factor: 11.205

9.  3D structure of the C3bB complex provides insights into the activation and regulation of the complement alternative pathway convertase.

Authors:  Eva Torreira; Agustín Tortajada; Tamara Montes; Santiago Rodríguez de Córdoba; Oscar Llorca
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-09       Impact factor: 11.205

10.  Insights into complement convertase formation based on the structure of the factor B-cobra venom factor complex.

Authors:  Bert J C Janssen; Lucio Gomes; Roman I Koning; Dmitri I Svergun; Abraham J Koster; David C Fritzinger; Carl-Wilhelm Vogel; Piet Gros
Journal:  EMBO J       Date:  2009-07-02       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.